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INTRODUCTION 
 
Copper related liver disease is one of the most common etiologies of liver disease 
in  India.  
 
Wilsons disease (WD) is the most common of the copper related liver diseases. It 
is a genetic disorder which follows  autosomal recessive inheritance. WD is 
characterized by a mutation in ATP 7B gene at 13 q 14. WD generally presents as 
persistently elevated aspartate / alanine aminotranferases , chronic hepatitis, 
compensated or decompensated chronic liver disease or rarely it may present as 
Acute Wilsonian crisis. WD is diagnosed by Serum Ceruloplasmin levels, KF ring, 
24 hr urinary copper level, hepatic copper quantification and / or ATP 7 B 
mutation analysis. WD is treated by copper chelation either with Pencillamine or 
Zinc or both.  
 
Indian childhood cirrhosis ( ICC) has fascinated the medical fraternity for almost 
100 years. The peculiar features, enigmatic etiology and uniformly fatal outcome 
had frustrated many. In 1978, a finding almost by chance revealed a striking 
association of exceedingly high hepatic copper content. This finding led to the 
hypothesis that milk contaminated with copper caused the disease. It was 
characterized by occurrence of the disease in the infants with dietary history of 
dietary copper consumption. It is largely disappearing in India because of  
preventive strategies.  
 
There is a heterogeneous group of patients who do not fit into either  WD or ICC. 
There are case reports of this uncommon disease from other countries also. It was 
described in Austria , Germany, Saudi Arabia, Kuwait, Japan and USA. In India 
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largely after the disappearance of ICC it was described as Atypical copper 
cirrhosis. It is characterized by unexplained liver disease after the 5 years  but 
below 20 years of age with elevated hepatic copper content despite normal copper 
studies. There are very few reports until now of this peculiar and interesting 
disease in India. It is still unknown whether it is a milder, adult form of ICC . The 
causative factors, clinical profile or treatment outcome are still unknown . There 
was a report of cluster of 138 infants and young children who died from an 
endemic infantile liver cirrhosis in  Western Austria between 1900 and 1974. This 
disorder, Tyrolean infantile cirrhosis as described by Muller was clinically and 
pathologically indistinguishable from ICC . It followed autosomal recessive 
inheritance. Cow’s milk fed to the children was contaminated with copper from 
untinned copper or brass vessels. Muller described it as an Eco genetic disorder 
which has  largely been eradicated through the preventive strategies.  
 
 
The aim of the present study was to recruit such patients and look into causative 
factors such as increased dietary copper in the form of history of milk boiled in 
untinned copper or brass vessels and by measuring drinking water copper levels 
from  birth. The clinical profile and response to copper chelation  were also 
assessed. 
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WILSON’S DISEASE 
                            
 
                             Wilson’s disease is a rare autosomal recessive genetic disorder 
of copper metabolism, which is characterised by hepatic and neurological disease. 
The disease affects between one in 30 000 and one in 100 000 individuals, and was 
first described as a syndrome by Kinnier Wilson in 1912.1 Most symptoms first 
appear in the second and third decades of life. In affected individuals, there is 
accumulation of excess copper in the liver caused by reduced excretion of copper 
in bile. The great danger is that Wilson’s disease is progressive, can remain 
undiagnosed, and is fatal if not treated. 
 
Pathology 
                               In the early stages before cirrhosis develops, histologic findings 
in the liver consist of steatosis, focal necrosis, glycogenated nuclei in hepatocytes, 
and sometimes apoptotic bodies. As parenchymal damage progresses, possibly 
through repeated episodes of lobular necrosis, periportal fibrosis develops. 
Cirrhosis is usually macronodular but may be micronodular. 
Early in the course of WD, hepatocellular copper is bound mainly to 
metallothionein and distributed diffusely in the cytoplasm of hepatocytes; 
therefore, results of histochemical stains for copper are negative. As the disease 
progresses, copper exceeds the capacity of metallothionein and is deposited in 
lysosomes. These lysosomal aggregates of copper can be detected by special 
staining techniques for copper or copper-binding protein (such as rubeanic acid or 
orcein). Copper is usually distributed throughout the hepatic lobule or nodule, but 
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in the cirrhotic liver, some areas may have no stainable copper at all. If the clinical 
presentation mimics that of autoimmune hepatitis, liver biopsy specimens reveal 
classic histologic features of chronic hepatitis, such as interface hepatitis. 
Inflammation may be severe. Results of Mallory staining for hyalin may be 
positive, and hepatocellular copper accumulation may be detected. In patients who 
present with fulminant hepatic failure, liver biopsy confirms preexisting liver 
disease; cirrhosis may be present; and parenchymal copper is located mainly in 
Kupffer cells rather than  in hepatocytes. 
Changes in hepatocellular mitochondria, identified with electron microscopy, are 
an important feature in Wilson disease.2 The mitochondria vary in size; the 
numbers of dense bodies in mitochondria may be increased. The most striking 
change is dilatation of the tips of the mitochondrial cristae as a result of separation 
of the inner and outer membranes of the cristae, so that the intercristal space is 
widened to an irregular cystic shape. The crista resembles a tennis racquet if only 
the tip is dilated. Involvement of hepatocytes may not be uniform, so abnormalities 
may be found in some hepatocytes in some lobules and not in others. The 
mitochondrial changes are probably a consequence of oxidative damage from 
excessive liver copper. 
Left panel: Low power shows portal fibrosis, mild portal inflammation, and fatty infiltration (Masson trichrome). 
Right panel: High power view shows fatty infiltration of hepatocytes and two glycogen nuclei (Masson trichrome). 
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Clinical features 
                          The age at onset of symptoms generally ranges from 6 to about 40 
years. Wilson disease with hepatic involvement has been identified in patients 
younger than 5 years and patients older than 60 years.  
Hepatic presentation 
                           Symptoms may be vague and nonspecific, such as fatigue, 
anorexia, and abdominal pain. Occasionally patients present with a self-limited 
clinical illness that resembles acute hepatitis, with malaise, anorexia, nausea, 
jaundice, elevated serum aminotransferases, and abnormal coagulation test results. 
Some patients have a his-tory of self-limited jaundice, apparently caused by 
unexplained hemolysis.  
Patients may present with severe, established chronic liver disease—
hepatosplenomegaly, ascites, congestive splenomegaly, a low serum albumin level, 
and persistently abnormal coagulation test results. Some patients have isolated 
splenomegaly without hepatomegaly. Many of these findings relate more to portal 
hypertension as a consequence of Wilson disease than to the metabolic disorder 
itself. 
WD may manifest in children and young adults as clinical liver disease 
indistinguishable from autoimmune hepatitis.3 As in autoimmune hepatitis, the 
onset may be acute. Fatigue, malaise, arthropathy, and rashes may occur; 
laboratory findings include elevated serum aminotransferase levels, a greatly 
increased serum immunoglobulin (Ig) G concentration, and detectable nonspecific 
 11
autoantibodies such as antinuclear and anti–smooth muscle (anti-actin) antibodies. 
Wilson disease must be specifically ruled out because the treatment of the two 
diseases is entirely different. With appropriate treatment, the long-term outlook for 
patients with Wilson disease that manifests as autoimmune hepatitis appears to be 
favorable, even if cirrhosis is present. 
WD may also manifest as fulminant hepatic failure, with severe coagulopathy and 
encephalopathy.4 Acute intravascular hemolysis is usually present, and renal 
failure may develop. Unlike fulminant viral hepatitis, fulminant Wilson disease is 
usually characterized by disproportionately low serum aminotransferase levels 
(usually much less than 1500 U/L) at the onset of clinically apparent disease. The 
serum alkaline phosphatase level is in the normal range or even low for age, and 
the serum bilirubin level is often disproportionately high as a result of hemolysis.5 
Slit-lamp examination of the eyes may demonstrate Kayser-Fleischer rings . 
Urinary copper excretion is greatly elevated. Affected patients do not show a good 
response to chelation treatment and require urgent liver transplantation; albumin 
dialysis and related techniques may serve as temporary procedures until liver 
transplantation can be performed.6  
Recurrent bouts of hemolysis may predispose to the development of gallstones.  
Children with unexplained cholelithiasis, particularly with small bilirubinate 
stones, should be tested for Wilson disease. Unlike other types of chronic liver 
disease, Wilson disease is rarely complicated by hepatocellular carcinoma. 
In patients who have predominantly hepatic disease, evidence of subtle neurologic 
involvement often can be found. Mood disturbance (mainly depression, but 
sometimes impulsive or neurotic behavior), deterioration in school performance or 
handwriting, and clumsiness may be identified through careful questioning of the 
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patient or his or her parents. A soft whispery voice (hypophonia) is another early 
feature of neurologic involvement. 
 
Neurologic presentation 
                               The neurologic presentation of Wilson disease tends to occur in 
the second and third decades or later but has been reported in children as young as 
6 to 10 years. Most patients with a neurologic presentation have hepatic 
involvement, albeit often asymptomatic. Neurologic involvement follows two main 
patterns, movement disorder and rigid dystonia.7 Movement disorders tend to occur 
earlier and consist of tremors, poor coordination, and loss of fine motor control. 
Spastic dystonic disorders generally develop later, with mask-like facies, rigidity, 
gait disturbance, and pseudobulbar involvement such as dysarthria, drooling, and 
swallowing difficulty. Intellect is not impaired. 
Psychiatric presentation 
                              As many as 20% of patients may present with purely psychiatric 
symptoms.8 These symptoms are highly variable, although depression is common. 
Phobias and compulsive behaviors have been reported; aggressive and antisocial 
behaviors may also be seen. 
Ocular signs 
                               The classic Kayser-Fleischer ring is caused by copper 
deposition in Descemet's membrane of the cornea. Copper is actually distributed 
throughout the cornea, but fluid streaming favors accumulation near the limbus, 
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especially at the superior and inferior poles and, eventually, circumferentially 
around the iris. A careful slit-lamp examination is mandatory.   
 
 
Kayser-Fleischer ring  
 
Copper deposition in the lens (sunflower cataract), which does not interfere with 
vision, may be seen on slit-lamp examination and, like Kayser-Fleischer rings, 
disappears with chelation therapy. Kayser-Fleischer rings may be absent in 15% to 
50% of patients with exclusively hepatic involvement and in presymptomatic 
patients, whereas most patients with a neurologic or psychiatric presentation of 
WD have Kayser-Fleischer rings; only 5% do not. Kayser-Fleischer rings are not 
specific for WD. They may be found in patients with other types of chronic liver 
disease, usually with a prominent cholestatic component, such as primary biliary 
cirrhosis, primary sclerosing cholangitis, auto-immune hepatitis, and familial 
cholestatic syndromes. Kayser-Fleischer rings have also been reported in patients 
with nonhepatic diseases. 
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Involvement of the other organs 
                                  WD can be accompanied by various extrahepatic disorders 
apart from neurologic disease. Episodes of hemolytic anemia can result from 
sudden release of copper into the blood. Renal disease, mainly Fanconi's 
syndrome, may be prominent. Findings include microscopic hematuria, 
aminoaciduria, phosphaturia, and defective acidification of the urine. 
Nephrolithiasis also has been reported. Arthritis, affecting mainly the large joints, 
may occur as a result of synovial copper accumulation. Other musculoskeletal 
problems are osteoporosis and osteochondritis dissecans. Vitamin D–resistant 
rickets may develop as a result of the renal damage. Copper deposition in the heart 
can lead to cardiomyopathy or cardiac arrhythmias. Sudden death in Wilson 
disease has been attributed to cardiac involvement but is rare. Copper deposition in 
skeletal muscle can cause rhabdomyolysis. Endocrine disorders can occur. 
Hypoparathyroidism has been attributed to copper deposition. Amenorrhea and 
testicular problems appear to result from WD itself, not from cirrhosis. Infertility 
or repeated spontaneous abortion may be a sign of WD. Pancreatitis, possibly 
resulting from copper deposition in the pancreas, may also occur. 
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Diagnosis of Wilson’s disease 
AASLD recommendations for diagnosis and screening for Wilson's disease9 
 
Clinical features:  
 
WD should be considered in any individual between the ages of 3 and 55 years 
(Wilson's disease has been diagnosed in patients in their seventies) with liver 
abnormalities of uncertain cause. Age alone should not be the basis for eliminating 
a diagnosis of WD. 
 
WD must be excluded in any patient with unexplained liver disease along with 
neurological or neuropsychiatric disorder. 
 
In a patient in whom WD is suspected, Kayser-Fleischer rings should be sought by 
slit-lamp examination by a skilled examiner. The absence of Kayser-Fleischer 
rings does not exclude the diagnosis of WD, even in patients with predominantly 
neurological disease. 
 
Diagnostic testing:  
 
An extremely low serum ceruloplasmin level (<50 mg/L or <5 mg/dL) should be 
taken as strong evidence for the diagnosis of WD. Modestly subnormal levels 
suggest further evaluation is necessary. Serum ceruloplasmin within the normal 
range does not exclude the diagnosis. 
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Basal 24-hour urinary excretion of copper should be obtained in all patients in 
whom the diagnosis of WD is being considered. The amount of copper excreted in 
the 24-hour period is typically >100 mcg (1.6 micromol) in symptomatic patients, 
but finding >40 mcg (>0.6 micromol or >600 nmol) may indicate WD and requires 
further investigation. 
 
Penicillamine challenge studies may be performed for the purpose of obtaining 
further evidence for the diagnosis of WD in symptomatic children if basal urinary 
copper excretion is <100 mcg/24 hours (1.6 micromol/24 hours). Values for the 
penicillamine challenge test of >1600 mcg copper/24 hours (>25 micromol/24 
hours) following the administration of 500 mg of D-penicillamine at the beginning 
and again 12 hours later during the 24-hour urine collection are found in patients 
with Wilson disease. The predictive value of this test in adults is unknown. 
Hepatic parenchymal copper content >250 mcg/g dry weight provides critical 
diagnostic information and should be obtained in cases where the diagnosis is not 
straightforward and in younger patients. In untreated patients, normal hepatic 
copper content (<40-50 mcg/g dry weight) almost always excludes a diagnosis of 
WD. Further diagnostic testing is indicated for patients with intermediate copper 
concentrations (70-250 mcg/g dry weight) especially if there is active liver disease 
or other symptoms of WD. 
 
Neurologic evaluation and radiologic imaging of the brain, preferably by MR 
imaging, should be considered prior to treatment in all patients with neurologic 
WD and should be part of the evaluation of any patient presenting with 
neurological symptoms consistent with WD. 
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Mutation analysis by whole-gene sequencing is possible and should be performed 
on individuals in whom the diagnosis is difficult to establish by clinical and 
biochemical testing. Haplotype analysis or specific testing for known mutations 
can be used for family screening of first-degree relatives of patients with WD. A 
clinical geneticist may be required to interpret the results. 
 
Diagnostic considerations in specific target populations:  
 
Patients in the pediatric age bracket who present a clinical picture of autoimmune 
hepatitis should be investigated for WD. 
 
Adult patients with atypical autoimmune hepatitis or who respond poorly to 
standard corticosteroid therapy should also be investigated for WD. 
 
WD should be considered in the differential diagnosis of patients presenting with 
nonalcoholic fatty liver disease or have pathologic findings of nonalcoholic 
steatohepatitis. 
 
WD should be suspected in any patient presenting with acute hepatic failure with 
Coombs-negative intravascular hemolysis, modest elevations in serum 
aminotransferases, or low serum alkaline phosphatase and ratio of alkaline 
phosphatase to bilirubin of <2. 
 
First-degree relatives of any patient newly diagnosed with WD must be screened 
for WD. 
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Approach to diagnosis of Wilson disease (WD) in a patient with unexplained 
liver disease  
 
 
 
 
 
 
 
Molecular testing means confirming homozygosity for one mutation or defining 
two mutations constituting compound heterozygosity. 
CPN: ceruloplasmin; KF: Kayser-Fleischer. 
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                                                Predictive value of diagnostic criteria of Wilsons disease 
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ATP7B gene 
 
 
Cloning of the Wilson disease gene (ATP7B) was accomplished by a combination 
of conventional linkage analysis,10 physical mapping of the relevant region of 
chromosome 13q14, and recognition of its high homology with the Menkes disease 
gene. 11,12 The coding region of the Wilson disease gene is 4.1 kilobases in length, 
with messenger RNA (mRNA) of about 8 kilobases. The product is a membrane P-
type adenosine triphosphatase (ATPase) that consists of 1443 amino acid residues 
and has a molecular mass of 160 kd. There are predicted to be six copper binding 
domains, a phosphorylation domain, an ATP-binding region, and eight 
transmembrane domains. All functionally important regions of the gene are 
conserved between bacteria and yeast. Mutations in the ATP7B gene result in 
retention of copper in the liver as well as impaired incorporation of copper into 
ceruloplasmin.  
 21
 
 
A model of the predicted product of the Wilson disease gene, ATP7B 
Additional proteins are involved in the intracellular transport of copper. Copper is 
not free in the cell but is transported to specific proteins by copper chaperones.13 
The chaperone ATOX1 transports copper to ATP7B. The study of inherited copper 
toxicosis in Bedlington terriers has identified a possible new component of the 
copper transport system. Affected dogs show clinical variability that ranges from 
death from hepatic disease at 2 to 3 years of age to less severe chronic disease to a 
very high level of hepatic copper without clinical consequences. The proposed 
defective canine gene was identified by positional cloning through the use of 
markers to identify a region containing the MURR1 gene.14 This deletion of one 
exon of the MURR1 gene is found in most, but not all, affected dogs.15  
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Mutation analysis 
More than 260 reported mutations in the ATP7B gene have been detected in many 
different populations by single-strand conformation polymorphism analysis or by 
sequencing of each of the 21 exons. 16,17,18 These mutations are recorded in the WD 
Mutation Database.19 High-throughput methods are making mutation analysis more 
feasible for this disease, as for many others. Mutation analysis can be carried out 
with approaches such as denaturing high-performance liquid chromatography20 or 
by high-throughput sequencing of either selected or all exons of the gene.  
The identification of one mutation may be adequate to confirm the diagnosis of 
WD, if (1) characteristic clinical symptoms and at least some biochemical features 
are present and (2) the one mutation detected is clearly established as a disease-
causing mutation. 
The majority of mutations identified to date in ATP7B are missense mutations 
(57%). Small deletions and insertion (28%), nonsense (7%), and splice site (8%) 
mutations occur throughout the gene.19 Various ethnic groups have different 
specific mutations. The common histidine1069glutamine (His1069Gln) mutation21 
is present at least in the heterozygous state in 35% to 75% of Europeans with 
Wilson disease; the higher rate is relevant only for Eastern Europe.22 Exon 8 of the 
gene is particularly rich in mutations in European populations; depending on the 
age of onset, at least one mutation can be identified in exon 8 in about 50% to 60% 
of patients.23 The mutation arginine778leucine is common in Chinese 
populations.24 Because no mutation is present in high frequency in Japanese and 
Mediterranean populations, mutation detection is more challenging in such 
populations. In some populations that have ethnic homogeneity or in which the 
spectrum of mutations is established, testing strategies can identify the mutations 
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in more than 90% of patients, as in Sardinians, among whom Wilson disease 
occurs with a frequency of 1 in 7000 live births.25 If the patient is clinically 
normal, has only slight signs of the disease, or has a late age of onset, that patient 
could actually be a heterozygote. However, up to now, heterozygotes have not 
been known to become clinically affected or to require treatment. 
No individual biochemical test is reliable for the identification of patients. In some 
cases, even all combinations of tests prove inadequate for a diagnosis. The use of 
molecular tests in patients with any clinical symptoms of the disease may become 
routine in the near future and is already feasible in some populations. 
Mutation analysis – Indian perspective 
 
The spectrum of ATP 7 B mutations in patients with WD, mostly from three 
southern Indian states and their family members were studied. The spectrum of 
ATP 7 B mutations were described including 11 novel mutations in Indian WD 
patients and were documented lack of single dominant mutation. Identical WD 
phenotype among siblings in 6 of 8 families with > 1 child affected by WD 
suggests that factors other than ATP 7 B mutation influence WD phenotype.26 
 
In eastern India ,  WD patients from 109 unrelated families and their first-degree 
relatives comprising 400 individuals were enrolled to study the spectrum of ATP 
7B mutations. In addition to previous reports, eight mutations including three novel 
(c.3412 + 1G > A, c.1771 G > A, c.3091 A > G) variants were identified. 17 
mutations were identified in eastern India including five common mutations that 
account for 44% of patients. Comparative study on WD mutations between 
different regions of India suggests high genetic heterogeneity and the absence of a 
single or a limited number of common founder mutations. Genotype–phenotype 
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correlation revealed that no particular phenotype could be assigned to a particular 
mutation and even same set of mutations in different patients showed different 
phenotypes.27  
 
In north west states of India there was absence of common mutations  H1069Q, 
R778W and R778L mutations in  WD patients. R778W and I1102T mutations 
were present in 36% of WD patients.28 The copper ATPase activity in WD patients 
was significantly reduced (50%) than that of control individuals. No significant 
difference was observed in copper stimulated ATPase activity between 
homozygous (R778W/R778W, I1102T/I1102T) and compound heterozygous 
(R778W/unknown mutation, I1102T/unknown mutation) WD patients.28 
 
 
Treatment of Wilsons disease 
 
AASLD recommendations for treatment of Wilson's disease (WD)  
 
Initial treatment for symptomatic patients should include a chelating agent (D-
penicillamine or trientine). Trientine may be better tolerated. 
 
Patients should avoid intake of foods and water with high concentrations of copper, 
especially during the first year of treatment. 
 
Treatment of presymptomatic patients or those on maintenance therapy can be 
accomplished with a chelating agent or with zinc. Trientine may be better 
tolerated. 
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Patients with acute liver failure due to WD should be referred for and treated with 
liver transplantation immediately. 
 
Patients with decompensated cirrhosis unresponsive to chelation treatment should 
be evaluated promptly for liver transplantation. 
 
Treatment for WD should be continued during pregnancy, but dosage reduction is 
advisable for D-penicillamine and trientine. 
 
Treatment is lifelong and should not be discontinued, unless a liver transplant has 
been performed. 
 
For routine monitoring, serum copper and ceruloplasmin, liver biochemistries and 
international normalized ratio, complete blood count and urinalysis (especially for 
those on chelation therapy), and physical examination should be performed 
regularly, at least twice annually. Patients receiving chelation therapy require a 
complete blood count and urinalysis regularly, no matter how long they have been 
on treatment. 
 
The 24-hour urinary excretion of copper while on medication should be measured 
yearly, or more frequently if there are questions on compliance or if dosage of 
medications is adjusted. The estimated serum non-ceruloplasmin bound copper 
may be elevated in situations of nonadherence and extremely low in situations of 
overtreatment.29 
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Penicillamine  
 D-Penicillamine contains a free sulfhydryl group that functions as a copper 
chelating moiety. Its major effect is to promote urinary excretion of copper, 
although it may also function by other mechanisms. Penicillamine reduces the 
affinity of proteins for copper, thereby allowing previously protein-bound copper 
to bind to penicillamine. It has also been used in the treatment of rheumatoid 
arthritis and cystinuria. 
Dosing — The drug should be introduced with incremental doses of 250 to 500 
mg/day increased by 250 mg increments every four to seven days to a maximum of 
1000 to 1500 mg daily in two to four divided doses. This regimen may reduce the 
incidence of early adverse side effects such as fever and rash, but does not appear 
to reduce the incidence of late-onset toxicity such as the nephrotic syndrome .A 
lower dose (750 to 1000 mg daily in two divided doses) is sufficient during the 
maintenance phase (usually after four to six months). The therapeutic response to 
changes in maintenance dosage usually will not become evident for six to eight 
weeks. The dose in children is 20 mg/kg per day (rounded to the nearest 250 mg) 
given in two or three divided doses. 
Penicillamine should ideally be given one hour before or two hours after meals 
since food interferes with its absorption. However, some patients may require 
dosing closer to food intake, which is an acceptable compromise if it increases 
compliance. 
Adverse effects  
Penicillamine is associated with multiple side-effects leading up to about 5 percent 
of patients to discontinue therapy. Other treatments should probably be used in 
patients who are at increased risk for toxicity including those with a history of 
renal disease, severe thrombocytopenia, or an autoimmune tendency. 
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Crossreactivity to penicillin may occur. Thus the drug should be used cautiously in 
patients with known penicillin allergy. 
Early sensitivity reactions (occurring within one to three weeks of beginning 
therapy) are characterized by fever, cutaneous eruptions, lymphadenopathy, 
neutropenia, thrombocytopenia, and proteinuria. The drug should be discontinued 
immediately in such patients and alternative treatment (principally trientine) 
begun.  
Several side effects occurring months to years after initiating therapy have also 
been described. The appearance of proteinuria may herald the onset of nephrotic 
syndrome, which may occur years after treatment begins. The onset of nephrotic 
syndrome necessitates cessation of the drug. However, protein excretion of up to 2 
g/day produces no symptoms and may not progress. Although cessation of therapy 
always leads to resolution of the proteinuria, the mean time required for this to 
occur is approximately one year and some patients take more than two years 30. A 
much less common but more serious renal complication is the development of a 
crescentic glomerulonephritis.  
Other later reactions include Goodpasture syndrome, bone marrow toxicity 
including severe thrombocytopenia or total aplasia, myasthenia gravis, 
polymyositis, hepatotoxicity, loss of taste, and a lupus-like syndrome characterized 
by hematuria, proteinuria, a positive antinuclear antibody. 
Skin changes have been described including elastosis perforans serpiginosa 
pemphigus, lichen planus, and aphthous stomatitis 31  
Nausea, vomiting, and anorexia are dose-related signs of gastric irritation and 
improve if the dose is reduced.  
Aplastic anemia is rare but may not reverse with the cessation of therapy.  
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The neurologic status of patients with predominantly neurologic symptoms 
worsens in approximately 10 percent of patients after beginning treatment 32. 
Furthermore, new neurologic symptoms may appear in some patients, although 
they are usually transient as long as chelation therapy is continued. These events 
may be caused by two potential mechanisms: mobilization of hepatic copper stores 
leading to increased brain copper exposure, or the development of intracellular 
copper complexes 33 . 
Penicillamine inactivates pyridoxine. Thus, small doses of pyridoxine, 25 mg per 
day, should be given to patients treated with penicillamine to prevent pyridoxal 
phosphate deficiency.  
Oral zinc — Oral zinc interferes with the absorption of copper, providing a 
rationale for its use in Wilson's disease. Zinc induces metallothionein (an 
endogenous chelator of metals) in enterocytes, which has a greater affinity for 
copper than for zinc, causing it to bind luminal copper and thereby preventing its 
entry into the circulation 34. The bound copper is excreted fecally during normal 
turnover of enterocytes. Zinc may also induce hepatic metallothionein 35. 
Dosing — There are several forms of oral zinc salts, which probably have similar 
abilities to interfere with copper absorption, but differ in their tolerability. Zinc 
acetate (Galzin, GATE Pharmaceuticals) causes the least gastrointestinal side-
effects while gluconate is more tolerable than sulfate. Dosing is in milligrams of 
elemental zinc. The dose of zinc acetate in adults and older children is a total of 
150 mg daily given in three divided doses. Smaller children (less than 50 kg body 
weight) should be given a total of 75 mg daily in three divided doses 36. The 
optimal dose for children younger than five is unknown. Dosing of zinc should be 
separated from food and beverages by at least one hour. 
Adverse effects — The most common adverse effect of zinc is gastrointestinal 
upset, appears to be least with zinc acetate. Hepatic deterioration (including a 
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fatality) has been described in case reports 37. Neurologic deterioration is 
uncommon. Elevation in serum amylase and lipase without clinical evidence of 
pancreatitis has been observed. 
Other drugs, such as Trientene and tetrathiomolybdate are recommended that are 
mainly useful when there are neurological symptomps which are aggravated by 
pencillamine. Potassium sulfide and carbacrylamine resins, which bind copper in 
the gastrointestinal tract, are not recommended. Dimercaprol (BAL), the first drug 
that successfully treated Wilson's disease, is rarely used. 
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Indian childhood cirrhosis 
                             
                           In October 1887, Boyle Chunder Sen38 presented the first clinical 
account of this condition, attributing it to some ‘inherited dyscrasia’. In the very 
next year, Gibbons performed the first autopsy, soon followed by three more. He 
designated the disease ‘Infantile Biliary Cirrhosis’, due to the presence of 
proliferated bile ducts, and ascribed it to some ‘endogenous chemical irritant’39 
which went unchallenged for over six decades. The detailed autopsy studies 
revealed several new and unique features40 like ‘Peri-cellular fibrosis’ in the liver, 
and raised suspicions of ‘congenital syphilis’, but was ruled out on the basis of 
‘negative serology’. Since  cirrhosis was also accompanied by ‘phlebosclerosis’ of 
some of the tributaries of the hepatic vein, the causative role of some exogenous 
‘plant toxins’ was invoked and  a new term‘Sub-acute toxic cirrhosis’ was 
introduced40. However in 1954, Bhende and Deoras described the presence of 
‘hyaline’ in autopsy liver samples and also designated the condition as ‘Infantile 
cirrhosis’41. Towards the end of 1970s, Tanner and associates modified the 
previous histochemical studies on ICC42, and reported an increase of Orcein +ve 
stainable hepatic Copper binding protein (CuBP)43. Finally in 1979, a new theory 
of ‘dietary copper toxicity’, based on elevated levels of hepatic copper, attributed 
to use of ‘copper yielding utensils’ was proposed44. Soon, the need to confirm the 
qualitative histochemical studies by ‘quantitative elemental analyses’ was felt and 
so the standard Atomic Absorption Spectrometry (AAS) Chemical Analysis was 
carried out on liver biopsy samples44. Almost simultaneously, Popper with the help 
of Delhi group carried out ‘AAS studies on three autopsy samples of ICC45. 
 
 
 31
 
Clinical and epidemiologic features of ICC 
 
The characteristic clinical and epidemiologic features of ICC are as follows46,47,48,49   
 
1.  The specific age range is from 6 months to 5yrs with a mean of 18 months 
 
2.  The disease is predominant in males.  
 
3. There are high rates of parental consanguinity in families affected with this     
disease, and up to 22% of siblings are affected.  
 
4. The disease is restricted to the Indian subcontinent, and the origin of cases is 
rural rather than urban. 
 
5. Distribution by religion and caste reflects the local rural population,but Muslims 
and Christians are mostly spared.  
 
6. The onset is mainly insidious (86%) with nonspecific complaints such as 
abdominal distention, irregular fever, excessive crying, and altered appetite. In a 
few children, the disease begins with jaundice, but this is usually a late feature. The 
feel of the liver is characteristically firm to hard with a sharp, “leafy” edge. 
Untreated, the progress is relentless and within a few months the affected child is 
desperately ill with hepatosplenomegaly, ascites, edema, and jaundice. An unusual 
late feature is an enlarged, palpable gall bladder, believed to be due to cholangitis 
and cholecystitis. Death is usually due to bleeding, secondary infection, or hepatic 
coma.  
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7. Standard liver function tests are usually abnormal but not diagnostic. Clinical or 
biochemical differentiation of early ICC from other childhood liver disorders such 
as unresolved viral hepatitis, chronic persistent or active hepatitis, veno-occlusive 
disease, and cryptogenic cirrhosis is difficult and hence histopathology remains the 
cornerstone of definitive diagnosis. 
 
Histopathology 
 
The striking orcein-rhodanine staining representing copper is seen consistently and 
easily in a simplified  histologic diagnosis of ICC50. The two most discriminatory 
features of ICC now recognized are widespread,coarse, dark-brown orcein staining 
and intralobular pericellular fibrosis 51. Hepatocytic necrosis (seen in 97% of cases) 
and hyaline (seen in 66% of cases) are also diagnostic though late features. Portal 
fibrosis, inflammation, and disruption of the limiting plate are seen in most cases, 
but are seen also in other liver disorders and hence are not of discriminatory value. 
Parenchymal fat is usually absent and cholestasis is a late feature52. 
 
Pathogenesis 
 
The increased copper in ICC may be secondary to liver damage and impaired 
biliary copper excretion 53,54 may be the result of an inherited disorder of copper 
metabolism akin to Wilson disease or may simply be the result of excessive copper 
intake. No studies to date have really substantiated the first two suggestions in 
typical ICC in India. However, many epidemiologic studies and feeding histories 
strongly support the copper-ingestion theory 55,56,57. Copper and brass (an alloy of 
70% copper and 30% zinc) vessels have been used extensively in India, especially 
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by traditional Hindu families. Experimentally, boiling and storing milk in untinned 
brass vessels raises its copper concentration more than 60 times-a gross copper 
contamination. Water takes up copper less avidly-storing water in a copper vessel 
raises its modest copper concentration only about six times55 . Ultracentrifugation 
and chromatography studies have shown that copper binds predominantly to 
casein, which is an exclusive constituent of milk. In acidic pH (as in gastric juice) 
casein liberates most of this bound copper, making it available for rapid absorption 
58. Boiling or storing milk or water in stainless steel or aluminum does not change 
the copper concentration. Traditional “kaIhai” or “tinning” of copper and brass 
vessels prevents copper contamination, yet this procedure is often neglected 
because of cost and effort. 
 
Prevention of Indian childhood cirrhosis 
 
The copper-ingestion hypothesis of ICC suggested the remarkable possibility that a 
fatal liver disorder could be eradicated through a simple message of health 
education. This was demonstrated in Pune through an extensive interventional 
study 59. A massive campaign of health education involving government and 
nongovernment health agencies (district health officials, multipurpose workers, 
Anganwadi workers, dairy societies, and adult education workers) was carried out 
in the entire Pune district from 1984 to 1987. Systematic surveys showed that the 
campaign reduced the use of brass vessels in the Pune district from 13% to 4%. 
This was associated with a significant fall in the number of cases of ICC from the 
Pune District seen at KEM Hospital. Dairy development and government milk 
schemes have led to replacement of the milkman’s brass vessels with aluminum 
canisters and glass or plastic bottles for milk supply. With urbanization and smaller 
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families now the norm, household brass vessels have been put away in favor of 
cheaper and hardier stainless steel or aluminum containers. 
 
Treatment of Indian childhood cirrhosis 
 
Therapeutic trials of the copper chelator D-penicillamine for ICC treatment have 
shown a remission in up to 65% of patients in the early (preicteric) stage of disease 
60. Remission is associated with clinical recovery, reduction in hepatic copper to 
normal concentrations, and striking histologic reversal of cirrhosis within a couple 
of years of therapy 61,62,63. Twenty-nine such survivors of ICC (followed up for 5-
12 y) have continued to do well despite the withdrawal of D-penicillamine after 3-  
5years of treatment  The continued well-being of ICC survivors without 
Dpenicillamine and the disappearance of ICC coincident with a decrease in the use 
of brass vessels for feeding strengthen the evidence that copper accumulation in 
ICC is an acquired phenomenon , rather than an inborn error of copper metabolism. 
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Recent views about ICC64 
 
The newly invoked theory of ‘dietary copper toxicity’ was found to be virtually 
untenable. Thus, in four of the six Centres, use of copper yielding utensils was 
reported in just 10 to 50 per cent of cases categorized as definitive ICC, a 
frequency not different from that in controls. In the remaining two Centres located 
in Mumbai, copper yielding utensils were not at all used for cooking and boiling or 
storing milk for any of the definitive ICC cases. Until they developed the disease, 9 
children with definitive or florid ICC were found to be purely breast-fed without 
any supplementation by milk or weaning diets. All the other stages of ICC were 
also encountered in the total absence of use of copper yielding utensils for cooking 
the food of affected children.  
 
                   The causative role of Cu has been dispelled. In view of the subsequent 
disappearance of the disease in the affected castes , the hypothesis of inherited 
susceptibility of copper metabolism also does not appear to be valid. Instead, the 
possible hepato-toxic effects of post-puerperal domestic therapeutic remedies 
appear to be more plausible. The current efforts at identification of the 
incriminated compound(s) in specific herbal formulations, by appropriate animal 
experiment, will resolve the mystery of ICC. 
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Atypical copper cirrhosis 
 
There is a heterogenous condition which neither fits into WD nor ICC described as 
Atypical copper cirrhosis.(ACC) 
 
In 1995 Bhanumathy Ramakrishna et al65 working on liver biopsies in children 
with cryptogenic cirrhosis found that they have copper deposition in the liver with 
out either WD or ICC , as defined according to the accepted clinicopathological 
findings in these conditions. The children with ACC presented at a mean age of 9.8 
years with abdominal distension and organomegaly with or with out ascites or 
jaundice. None had Kayser Fleisher rings. Serum and urine copper levels were 
elevated only in 2 of 7 children studied. Serum ceruloplasmin levels were normal 
or increased . No history of possible excess copper ingestion was obtained except 
in the case of one child whose family used brass vessels to store drinking water. 
 
Pathology  
 
Tissue from patients with ACC showed micronodular cirrhosis . Fatty change was 
absent from all the biopsy samples. Varying degrees of pericellular fibrosis, 
ballooning of hepatocytes and Mallory’s hyaline were seen. Stainable copper or 
copper associated protein was present in all the biopsies. 
 
All patients received copper chelation with improvement of symptoms. 
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ICC like cirrhosis 
 
Recent reports of ICC-like cirrhosis with raised hepatic copper concentrations in 
Western countries have raised doubts yet again about the copper-ingestion theory 
of ICC 66,67,68,69. Although copper-contaminated water (copper pipes and water with 
a low pH) has been incriminated in a few cases, the amount of copper ingested 
does not match that in ICC in India. 
ICC like illness was seen in Austria70 , Kuwait71, Saudi Arabia72 ,  Japan73 and 
Germany74.  
 
Endemic infantile Tyrolean cirrhosis70 
 
                               138 infants and young children died from an endemic infantile 
liver cirrhosis in a circumscribed rural area of western Austria between 1900 and 
1974. Frequency of the disease peaked between 1930 and 1960. It has disappeared 
from this area since 1974. Clinical and genetic data on the patients was gathered; 
pedigrees analysed and ethnographic studies and interviews were undertaken. The 
disease, which was clinically and pathologically indistinguishable from Indian 
childhood cirrhosis and hepatic copper toxicosis, was transmitted by autosomal 
recessive inheritance. Cow's milk, contaminated with copper from untinned copper 
or brass vessels, may have contributed to the development of copper toxicosis. 
Replacement of untinned copper cooking utensils by modern industrial vessels has 
eradicated the disease.  
The findings strongly suggest that the endemic Tyrolean childhood cirrhosis-and 
by analogy non-Wilsonian hepatic copper toxicosis occurring elsewhere-is an 
ecogenetic disorder requiring the involvement of both genetic and environmental 
factors for the disease to become manifest. 
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Aims of the study 
 
 
 
 
 
 
1. To look for evidence of increased copper intake in Atypical copper 
related liver disease (ACLD ) patients. 
 
 
 
2. To study clinical features and treatment outcome of ACLD 
patients.  
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Materials and methods 
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This study was conducted in Department of Clinical gastroenterology and 
hepatology, Christian medical college , Vellore. It was approved by institutional 
research and ethics committee ( Institutional review board).  
 
Study design : 
 
Prospective descriptive study 
 
 
 
 
     Time period : 
 
From Dec 2006 to Dec 2008 
 
 
 
 
Inclusion criteria : 
 
Patients with chronic liver disease with significant stainable copper deposits83 
aged less than 20 yrs and more than 5 years 
  
 
 
 
    Exclusion criteria: 
 
Wilson’s disease 
Indian Childhood Cirrhosis 
Biliary diseases 
Positive  viral markers 
Active alcohol intake 
Age more than 20 yrs 
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Subjects: 
 
 
                       Patients presenting to outpatient and / or inpatient department of  
Clinical gastroenterology and hepatology , Christian medical college , Vellore 
from Dec 2006 to Dec 2008 with the confirmed diagnosis of Atypical copper 
related liver disease were included in the study after informed consent.   
 
 
                       All patients were subjected to etiological evaluation including 
liver biopsy. Patients with Wilsons disease  (leipzig criteria), Indian childhood 
cirrhosis and cholestatic disorders were excluded from the study 
 
                       Dietary history was obtained in all the subjects. Whether drinking  
water was  stored  in  brass  vessels ( tinned or untinned) or cooking  was done 
using brass vessels (tinned or untinned) was obtained in all the subjects. 
 
                  Drinking  water  was obtained from different regions of residence 
right from the  birth of the study patients. Drinking water was tested for copper 
content using flame atomic absorption spectrometry 
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Diagnostic criteria of Atypical copper related liver disease 
 
 
Atypical copper related liver disease was defined as unexplained liver disease 
a) In 5 - 20 years old patients  
b) Significant copper deposits on liver biopsy83 (by Rhodanine/Orcein stain) 
c) Normal or high serum ceruloplasmin, 
d) No Kayser Fleischer ring,  
e) Absent ATP7B mutation   
f)  Histological features not consistent with WD or ICC on liver biopsy, and 
g) No history of  copper ingestion (cooking in brass vessels). 
11  patients  were   included   in   the  study  who  satisfied   the  above   criteria. 
 
Drinking water sample Collection Procedures75 
 
 
                         Samples were collected from water taps that were undisturbed for 
at least six hours, but no more than 12 hours. Therefore, patients were asked to 
take samples first thing in the morning. This minimum six-hour standing time 
helps to standardize the test results. Copper levels increase as long as water stands 
in a home’s plumbing system. Water that stands longer than 12 hours may have 
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high  copper levels that do not represent typical conditions. The action level is 1.3 
mg/L for copper.  
Standardized containers for specimen collection were provided to the patients from 
our institution. 
 
 
Measurement of serum ceruloplasmin 
 
The methods used to measure ceruloplasmin were o-dianisidine dihydrochloride 
method 82 before 1st Nov 2007 (normal range , 62 – 140U/L) and ferroxidase 
method76 on and after 1st Nov 2007(normal range , 200 – 1100 U/L)  . 
 
O-DIANISIDINE DIHYDROCHLORIDE METHOD82 :  
 
Principle of the test : 
O-dianisidine dihydrochloride (4,4’-diamino-3,3’-dimethoxy -biphenyl) is used as 
a substrate. This reagent which requires no purification of the commercially 
available material and is stable in aqueous solution, is converted into a yellowish-
brown (16 ) reaction product in the presence of ceruloplasmin and oxygen at pH 5. 
Acidification stops the enzymatic reaction, and a stable purplish- red (16 ) solution 
is formed that absorbs maximally at 540 nm. This is read using spectrophotometer.  
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Procedure 
Pipet 0.75 ml of acetate buffer and 0.05 ml of serum into two tubes (one marked “5 
min,” and the other “15 min”). Place the tubes in a 300 C water bath. Allow 5min 
for temperature equilibration before pipetting, at timed intervals, 0.2 ml of o- 
dianisidine dihydrochloride reagent (pre-incubated at 300 C) into each tube, 
starting the timer at the first substrate addition. After exactly 5 min remove the “5 
min” tube from the water bath, add 2.0 ml of the 9 molar sulfuric acid, and mix 
immediately. At exactly 15 min remove the “15 min” tube, add 2.0 ml of the 9 
molar sulfuric acid and mix immediately. Measure the absorbance of the purplish-
red solutions at 540nm, in a cuvet having a 1-cm light path vs. de-ionized water as 
a blank. 
 
FERRO OXIDASE METHOD76 : 
 
 
Analyzer : Hitachi 912 
 
 
Summary & explanation of the test 
 
Functional ceruloplasmin or copper oxidase, is measured colorimetrically using the 
reaction of ferene with ferrous ions remaining after the ferroxidase of 
ceruloplasmin The method used is a fixed time kinetic, with a 2 point inverse 
calibration. 
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Principle of the method 
The chromogen is 3-(pyridyl)-5,6-bis (2-(5-furyl sulfonic acid ) ) – 1,2,4-tri – azine 
, disodium salt. The serum sample is incubated with a known amount of ferrous 
ions, which are oxidized to ferric ions  by the enzyme. The chromagen forms a 
highly colored complex with ferrous ions , but not with ferric ions. 
 At the end of the incubation period , the chromgen is added and the remaining non 
oxidized ferrous ions measured photometrically. The difference in the ferrous ion 
concentration before and after the enzymatic reaction indicates the amount of 
oxidized ferrous ion. 
 
Measurement of 24 hr urinary copper77 
 
 
Principle of the method 
 
 
When a diluted serum sample is aspirated into an atomic absorption 
spectrophotometer , “ the ground state “ atom absorbs light energy of a specific 
wavelength as it enters the excited state. As the number of atoms in the light path 
increases , the amount of light absorbed also increases. By measuring the amount 
of light absorbed  also increases. By measuring the amount of light absorbed , a 
quantitative determination of copper in the sample could be made. 
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Sample preparation 
A 1:2 diluted urine ( 1 ml urine + 1ml of deionised water ) is directly aspirated and 
the reading obtained is then compared with a copper standard containing 2mg/L for 
serum copper and 200 ug/L for urine copper respectively. Multiply the value 
obtained x2 to get the final value. 
 
 
Measurement of drinking water copper level84 
 
 
This method is based on the cloud-point extraction (CPE) technique for the trace 
analysis  of Cu in water samples .The analytes in the initial aqueous solution are 
complexed with pyrogallol, and 0.1%(w/v) Triton X-114 is added as surfactant. 
Following phase separation at 50oC, based on the cloud point of the mixture and 
dilution of the surfactant-rich phase with acidified  methanolic solution, the 
enriched analytes are determined by flame atomic absorption spectrometry. 
 
Kayser Fleisher (KF) ring examination : 
 
KF ring  was examined by slit lamp examination by ophthalmologists in 
Department of Ophthalmology , Schell eye hospital, Vellore. 
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Liver biopsy : 
 
 
All ACLD patients were subjected to liver biopsy either via percutaneous route or 
transjugular route depending on the presence of coagulopathy and / or  ascites. The 
biopsy specimen was sent for histopathology and dry weight liver for  copper 
estimation .  
The presence of stainable copper and copper associated protein (CAP) was graded 
semi quantitatively83 as follows  
0     -  negative;  
1+   -  present in a few hepatocytes;  
2+   -  present in several hepatocytes;  
3+   -  abundant copper and CAP in most hepatocytes, usually visible on naked eye 
examination of the slide. 
If there is more than or equal to 2+ copper deposition on liver biopsy it was taken 
as significant copper deposition.  
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Estimation of dry weight liver copper : 86 
 
 
Principle of the test :  
 
The test is based on measuring copper from 15-mg (wet weight) sample of human 
liver  by atomic absorption spectrophotometry. The sample is digested with nitric 
acid (1.0 mol/liter), evaporated, and dilute HNO3 (10 mmol/Iiter) added. The 
reconstituted acid mixture is injected into the graphite tube atomizer for analysis of 
Cu . 
 
Tissue Processing : 
 
Portions of human liver tissue, normal on gross examination were frozen at -20oC 
until needed for analysis. Adjacent pieces were histologically examined. The 
portions of liver frozen were complete cross sections, about 3 cm thick, surrounded 
completely by capsule. Before digestion, the liver was thawed and the capsule 
stripped away, revealing  a clean, uncontaminated surface. The sample was placed 
in a dried, preweighed, acid-cleaned, 3-ml test tube and the wet weight of the tissue 
was then recorded. After this weighing, the tubes were placed in a beaker on a hot 
plate, and the beaker was covered with an inverted larger beaker. The air 
temperature  inside the larger beaker was 80oC. tissue was dried for 24 h to 
constant weight, cooled in a desiccator,and weighed. About 70% of the wet weight 
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was lost, leaving about 5.0 mg of dry liver tissue. One milliliter of 1.0 mol/liter 
HNO3 acid was then added, and the dried sample was acid digested on a hot plate 
at 80oC another 24 h. The 1.0 mol/liter HNO3 was then slowly evaporated on a hot 
plate and 2.0 ml of 10 mmol/liter HNO3 was added with vigorous mixing. The 
liver tissue almost always completely dissolved. Incomplete solubilization did not 
alter the analytical results. Analysis was delayed for 4-6 h after reconstitution. The 
concentration of the three metals in the tissue was such that only 30 ul of the 
reconstituted solution of liver tissue was used for Cu analysis.  
 
A Model 303 atomic absorption spectrophotometer and a graphite tube atomizer 
was used for all Cu analyses. 
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ATP 7B mutation analysis – assay procedure 
 
 
Overview of the test : 
 
DNA was isolated from peripheral blood leukocytes of the  patients after  obtaining 
informed consent. DNA samples were electrophoresed on Agarose gel to confirm 
DNA isolation. All the exons (21 exons of ATP7B gene) were amplified by 
Polymerase Chain Reaction PCR product heteroduplexed with control DNA 
sample. Conformation Sensitive Gel Electrophoresis was done for heteroduplexed 
sample.      
 
 
Conformation Sensitive Gel Electrophoresis (CSGE) (mutation screening) 
  
The 21 exonic and flanking intronic regions of ATP7B gene were amplified by 
polymerase chain reaction using described primers78,79 . Each 25µl reaction 
contained 12.5µl of 2X ready reaction mix and the concentration of the primers 
used for each reaction and the annealing temperatures are shown in Table 1. 
Following an initial denaturation at 95oC for 5 minutes, 35 cycles of PCR 
amplification at 94oC for 40 seconds, a 40 seconds annealing at the temperature 
shown in Table 1 and extension at 72oC for 40 seconds were performed.  
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 To our knowledge, this is the first study reporting the use of CSGE to screen 
for ATP7B mutations in Atypical copper related liver disease subjects80 . Briefly, 3 
µl of PCR product from each patient was mixed with an equal volume of PCR 
product from a sequenced normal control correlating with the gene bank. Samples 
were denatured at 95oC for 5 minutes and then incubated at 55oC for 45 minutes to 
allow heteroduplex formation. 3 µl of heteroduplexed samples were mixed with 2 
µl of loading buffer and loaded onto a 10% CSGE gel. To attain the equilibration 
of the buffer throughout the gel 1hour pre-run was given with 750 V/cm. 
Following electrophoresis (450 V/cm, 17 hours), bands were visualized by 
ethidium bromide staining and samples displaying abnormal CSGE profiles 
relative to that in a normal individual were sequenced using ABI310 genetic 
analyzer.  
 
 
Table 1: Amplimers and Annealing Temperature for CSGE analysis and sequencing 
Exon  Amplimers     Annealing Temperature 
 
1 5’TTCCCGGACCCCTGTTTGCT3’   56C 
5’AATCCTCCTGGTGGGAGTGAG3’   
      2a        5’GTTTCAAGGTTAAAAAATGT3’   45C 
        5’GGCACATATTTCACAGTGG3’ 
      2b        5’GGCCACCAGCACAGTC3’    59C 
        5’CTGGGCAGGCAAGGAC3’ 
      2c        5’GAGGCCAGCATTGCAGA3’   50C 
                              5’AGCCACTTTGCTCTTGATG3’  
      2d        5’ATGACATGGGATTTGAAG3’   48C 
        5’TCCGACAGGAAGAGAAAC3’ 
      2e                   5’GCCCAAGTAAAGTATGACCC3’   50C 
        5’GACACCGATATTTGCTGCAC3’ 
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      2f        5’AGGGCTACCTATACACCATCC3’   50C 
        5’AGGGCTACCTATACACCATCC3’ 
      3        5’GATATTTCTGACATTTTATCC3’   45C 
      5’GCAGCATTCCTAAGTTCA3’ 
      4        5’CCACCCAGAGTGTTACAGCC3’   52C 
        5’ACCCCCTAACGCACCCA3’ 
      5        5’CCTGGGTCTGTGGGATTCT3’   50C 
        5’AAAGGTGACTACAATTTTTAATGA3’ 
      6        5’CTGCCAATGCATATTTTAAC3’   50C 
        5’GGTAGAGGAAGGGACTTAGA3’ 
      7        5’TGTAATCCAGGTGACAAGCAG3’   52C 
        5’CACAGCATGGAAGGGAGAG3’ 
      8        5’AACCCTTCACTGTCCTTGTC3’   48C 
              5’AGGCAGCTCTTTTCTGAAC3’ 
      9        5’TTTCGATAGCTCTCATTTCACA3’   50C 
        5’TGCCCACACTCACAAGGTC3’ 
      10        5’AGTCGCCATGTAAGTGATAA3’   48C 
        5’CTGAGGGAACATGAAACAA3’ 
      11        5’CTGTCAGGTCACATAGTGCT3’   50C 
        5’TTTCCCAGAACTCTTCACA3’ 
      12        5’CTTGTGTGTTTTATTTCTTC3’   48C 
        5’ACCACCATATAGCCCAAG3’ 
      13        5’TGAACTCTCAACCTGCCT3’   50C 
        5’TCTCAGATGGGAAAGCCG3’ 
      14              5’TCCATCTGTATTGTGGTCAG3’   50C 
        5’CAGCTAGGAGAGAAGGACAT3’ 
      15              5’CTTTCACTTCACCCCTCT3’    48C 
                 5’AGCTGACAGAGACAAAAGC3’ 
      16        5’CCATTTAGAAATAACCACAG3’   48C 
        5’AGGAAGGCAGAAGCAGA3’ 
      17        5’CAAGTGTGGTATCTTGGTG3’   50C 
              5’CTGGTGCTTACTTTTGTCTC3’ 
      18        5’ACCTTTTGCCAACACTAGCAT3’   52C 
        5’TCCCAGCACCCACAGCC3’ 
       19        5’GGCAGACCCCTTCCTCAC3’   55C 
        5’CCTGGGAGAGAGAAGCCTTT3’ 
       20        5’CTAGGTGTGAGTGCGAGTT3’   50C 
        5’CAGCATTTGTCCCAGGT3’ 
       21        5’AATGGCTCAGATGCTGTT3’   50C 
        5’GCTTGTGGTGAGTGGAGG3’ 
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  Fig 1 , CSGE results of exon 11 in three patients 
 
 
 
   
   Fig 2 , CSGE results of exon 19 in three patients 
 
    
 
Mutation confirmation ( by sequencing) 
 
As none of the samples tested, showed aberrant patterns ( hetero duplex formation) 
on CSGE ; sequencing  of the gene was not done. 
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Follow up of these patients 
 
 
 
All patients diagnosed to have ACLD were treated with copper chelation , either 
D-Penicillamine or Zinc or both sequentially and followed up .  
 
During each follow up the patient was examined clinically and investigated 
biochemically using liver function tests, 24 hr urinary copper,complete blood 
profile, prothrombin time and with calculation of MELD and CTP score. 
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Results 
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11 patients are included according to the diagnostic criteria for Atypical copper 
related liver disease (ACLD). 
 
Characteristics of  the patients with ACLD are shown in Table 2. 
 
 
 
Table 2 : Patient characteristics 
 
S.No 
 
   
 Age/ Sex  
 
Age at the 
onset of 
illness  
 
Date of 
illness 
 
Date of first 
CMC visit  
 
Date of 
treatment 
1 
 
22/ M 
 
20 
 
Sep 06 
 
Sep 06 
 
Sep 06 
2 
 
9 / M 
 
9 
 
Sep 07 
 
Oct 07 
 
Oct 07 
3 
 
18 / F 
 
16 
 
Jun 05 
 
Apr 07 
 
Apr 07 
4 
 
15 / M 
 
15 
 
Aug 07 
 
Sep 07 
 
Oct 07 
5 
 
9 / M 
 
8 
 
Mar 06 
 
Mar 07 
 
Mar07 
6 
 
15 / M 
 
7 
 
Oct 99 
 
Oct 99 
 
Dec 99 
7 
 
15 / F 
 
7 
   
Oct 99 
 
Dec 99 
8 
 
13 / M 
 
5 
   
Oct 99 
 
Dec 99 
9 
 
24 / F 
 
20 
 
       Jun 03 
 
Jun 07 
 
Jul 07 
10 
 
23 / M 
 
20 
 
      Jan 05 
 
Jan 08 
 
Mar 08 
 
11 
 
10 / F 
 
7 
 
      Aug 04 
 
Sep 04 
 
Sep 04 
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11 ACLD patients from 9 families were studied. 8 of them were from Tamil Nadu, 
2 were from  Andhra Pradesh and 1from Kerala. In 1 family, all 3 children 
(including a twin pair) had ACLD, while in another family an elder sibling died of 
unexplained liver disease. There were  7 males and 4 females , median  age was 16 
, 9 – 24 years (median, range) . Although the age range was more than 20 years , 
these patients were included because of their disease presentation at less than 20 
years of age. 
 
                   Fig 3.  Distribution of patients by state of origin 
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Clinical profile of the patients :  
All patients were symptomatic during their presentation except 2 , who were 
asymptomatic siblings of a patient. 
All patients presented with jaundice , 6 had hepatic decompensation in the form of 
ascites, one patient had hepatic encephalopathy at presentation, none had 
neurological involvement and coomb’s negative heamolytic aneamia. 
During the follow up two patients developed variceal bleeding and received 
endotherapy. 
 
Patients Asympto
matic  
Hepatic presentation  Neurological 
       
AH 
 
CLD 
 
Complications 
 
     
Ascites 
 
Coma 
 
GIbleed 
 
1 - - √ √ - √ - 
2 - √ - - - - - 
3 - √ √ √ √ - - 
4 - √ - - - - - 
5 - - √ √ - - - 
6 - - √ √ - √ - 
7 √ - - - - - - 
8 √ - - - - - - 
9 - - √ √ - - - 
10 - - √ √ √ - - 
11 - - - - - - - 
 
Table 3 : Clinical presentation of patients 
 AH     – Acute hepatitis 
 CLD   – Chronic liver disease  
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Investigations : 
 
 
Table 4 shows the investigative profile of these patients. 
 
 
 
S.No  
 
 
KF 
ring 
 
 
Ceruloplasmin* 
           ( U/L ) 
 
24 hr 
urine 
copper@ 
(ug /24 
hr) 
 
Dry wt 
copper 
liver# 
( ug/g ) 
 
 
Serum 
Copper 
ug/dl$ 
 
 
ATP 7B 
mutation 
 
Rhodanine
Staining 
on liver 
biopsy 
 
Rhodanine
Staining 
on liver 
biopsy 
 
1 
 
Neg  
 
175a 
 
145 
 
813  
    103  
Neg 
 
Present 
 
Present 
 
2 
 
Neg   
 
129a 
 
1272 
 80   
Present 
 
Present 
 
3 
 
Neg  
 
50a 
 
78 
 56 
 
 
Neg  
 
Present 
 
Present 
 
4 
 
Neg  
 
81a 
 
809 
 
596 
-   
Absent 
 
Absent 
 
5 
 
Neg  
 
59a 
 
21 
 -   
Present 
 
Present 
 
6 
 
Neg  
 
92a 
 
94 
  92 
 
 
Neg  
 
Present 
 
Present 
 
7 
 
Neg  
 
78a 
 
87 
  120 
 
 
Neg  
 
Present 
 
Present 
 
8 
 
Neg  
 
176a 
 
68 
  136 
 
 
Neg  
 
Present 
 
Present 
 
9 
 
Pos 
 
104a 
 
189 
 
449  
 
- 
 
Neg  
 
Present 
 
Present 
 
10 
 
Neg  
 
379b 
 
95 
 
390 
-   
Present 
 
Present 
 
11 
 
Neg  
 
62a 
 
122 
  40   
Present 
 
Present 
 
 
* a – ceruloplasmin measured by  O – dianisidine dihydrochloride method before 1st Nov 2007 
                                                                                                        normal range , 62 – 140 U/L                               
* b – ceruloplasmin measured by  Ferroxidase method on and after 1st Nov 2007 ,  
                                                                                normal range, 200 -1100 U/L  
@ 24 hr urine copper , normal range 40 -100 ug / 24 hr 
#   Dry wt. liver copper , normal range  < 250 ug / g 
$  Serum copper level normal range 70- 170 ug /dl 
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Serum ceruloplasmin was normal in 9 patients, borderline low in 2 patients.KF 
ring was absent in all patients except 1. 24 hr urine copper was normal in 6 
patients. Elevated 24 hr urine copper (152, 122 - 189µg) ( median , range ) was 
seen at baseline in 3 patients and in 2 patients although base line urine copper was 
normal, there was elevation after penicillamine challenge test . All 11 patients had 
copper deposits in liver biopsy. Rhodanine or orcein positivity was seen in all the 
patients except 1. Elevated dry weight copper was seen in 4 specimens tested (562, 
320-813 µg/gm) (median, range ).ATP7B mutations were absent in 6 patients 
tested. 
Leipzig scoring : 85 
Leipzig scoring system for the diagnosis of wilsons disease is based on the 
following variables 
        ceruloplasmin 
        24 hr urine copper 
        KF ring 
        Hepatic copper content 
        Rhodanine stain on liver biopsy 
        coombs negative heamolytic aneamia 
        mutational analysis  H1069Q (exon 14) 
 62
        neurological symptoms 
   
 
Table 5 Leipzig scoring 
 
A total score of   4   is considered as   Wilsons disease 
                            2-3 likely to have     Wilsons disease 
                            0-1 unlikely to have  Wilsons disease 
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Table 6:  Leipzig scoring system for ACLD patients 
 
 
 
 
 
S.No 
 
 
 
 
Leipzig score 
1 4 
2 3 
3 2 
4 4 
5 2 
6 2 
7 1 
8 1 
9 4 
 
10 3 
 
11 2 
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Liver histology :  
Mallory’s hyaline, pericellular fibrosis , hepatocyte ballooning degeneration, 
absence of fatty change , moderate to severe inflammatory activity , bridging 
fibrosis and significant stainable copper deposition were the predominant 
histological features observed on the liver biopsy specimens. 
 
 
Fig 4 Orcein stain shows fine  granules of copper associated protein in 
periportal hepatocytes (Orcein X 400) in patient 6 
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Fig 5 Rhodamine stain shows  granular deposits of copper in periportal 
hepatocytes (Rhodamine X 400) in patient 6 
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Table 7 shows the histological features of all the patients. 
 
Patient Fattychange Pericellular 
fibrosis 
Mallory’s 
hyaline 
Ballooning 
degeneration 
CAP Presence of 
cirrhosis 
 
1 
 
- 
 
- 
√ √ 2+ √ 
 
2 
 
- 
 
√ 
√ √ 2+ √ 
 
        3 
 
- 
 
√ 
√  
- 
1+ √ 
 
4 
 
- 
 
- 
 
- 
√ 2+ √ 
 
5 
 
- 
 
- 
 
- 
 
- 
2+ √ 
 
6 
 
- 
 
- 
 
- 
√ 2+ √ 
 
7 
 
- 
 
- 
 
- 
 
- 
1+  
- 
 
8 
 
- 
 
- 
 
- 
 
- 
1+  
- 
 
9 
 
- 
 
√ 
√ √ 2+ √ 
 
10 
 
- 
 
- 
 
- 
 
- 
2+  
- 
 
11 
 
- 
          √ √  
- 
2+  
- 
 
Table 7 : Liver biopsy findings in all patients 
 
 
In three patients even though the copper staining was 1+ they were included in the 
study because of strong family history and normal copper studies.  
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Drinking water copper content : 
 
 
 
Drinking water copper was measured in all the samples collected from the 
residences of the patients right from birth. Those samples were collected and 
processed as described earlier using flame atomic absorption spectrometry based 
upon cloud point extraction. 17 water samples were obtained from different sites 
of residence from the 9 families. Copper content in drinking water was normal in 
all samples (2.32 µg/L, 0.32-8.9) (median, range ). 
 
Dietary history for copper intake : 
All ACLD patients were asked about history of cooking in brass vessels. History of 
storing drinking water in brass vessels was obtained in 1 family, cooking in brass 
vessels in none. 
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Table 8:  Drinking water copper levels 
 
 
 
 
 
 
 
S.No 
 
 
 
 
Drinking Water copper (ug/l) 
1 
 
2.86 
2 
 
2.36 
3 
 
4.04 
4 
 
1.08 
5 
 
0.32 
6 
 
0.7 
7 
 
0.7 
8 
 
0.7 
9 
 
1.22 
 
10 
 
2.68 
 
11 
 
8.9 
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Follow up of the patients :  
 
All ACC patients were treated with copper chelation either with D-Penicillamine 
or Zinc or both sequentially. They were followed up for a period of 41 months , 3 – 
108 months ( median, range ) 
During the follow up Mean MELD score was decreased from 13 at baseline to 8.5 
at median follow up of 41 months. 
Mean MELD score on followup
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Graph 1 showing Mean MELD score on followup of ACLD patients 
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Mean improvement in albumin level was  from 2.78gm/dl at baseline to 3.06gm/dl 
during the follow up 
Mean albumin level on follow up
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Graph 2 showing Mean Albumin levels on followup 
 
During the follow up, Mean CTP score was fallen down from 10 to 7.5 with 
median duration of 41 months. 
Mean CTP scores on follow up
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Graph 3 showing Mean CTP score on followup 
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Mean bilirubin and 24 hr urine copper levels were decreased from 2.7mg /dl  and 
145ug/24hrs at baseline to 1mg/dl and 129ug/24hrs during 41median months of 
follow up respectively. 
Mean Bilirubin on followup
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Graph 4 showing Mean Bilirubin on followup 
24 hr urine copper on followup
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Graph 5 showing Mean 24 hr urine copper levels on followup 
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Graph 6 showing duration of treatment with copper chelation 
Survival: 
During the follow up period Patient 1 had recurrent variceal bleed with hepatic 
decompensation ultimately succumbed to death at his home town. Patient 3 expired 
with end stage liver disease with persistent jaundice, recurrent encephalopathy and 
ascites , was on transplant list for the same. Patient 6 expired at his home town 
unrelated to liver disease. All the patients received Penicillamine initially except 3 
who were started on zinc directly. Penicillamine was given for mean duration of 18 
months followed by zinc for a mean duration of 27 months. 
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Discussion 
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This thesis reports 11 patients with atypical copper related liver disease  – an 
example of hepatic copper toxicosis, which does not fit either into typical Wilsons’ 
disease or Indian Childhood Cirrhosis. 
 
The hallmark of this group of patients is presence of increased copper on liver 
biopsy on staining and by dry weight copper estimation, with normal serum 
ceruloplasmin and absence of KF rings in the eye. Three of the 11 patients had a 
score of 4 by Leipzig criteria (which is diagnostic of Wilson’s disease). However, 
the significantly increased liver copper on staining and dry weight estimation 
accounted for a score of 2, in the 3 patients with Leipzig score of 4. 
 
In this study the clinical presentation and treatment outcome of ACLD was 
described. In addition to that it was hypothesized that whether these patients were 
taking excessive amounts of copper in the form of cooking in brass vessels or 
increased levels of copper in the drinking water. 
 
The clinical presentation was no different phenotypically from any other form of 
liver disease or Wilsons’disease as far as hepatic presentation is concerned. All 
patients presented with jaundice except two who were asymptomatic siblings. 6 
patients had hepatic decompensation . All were treated with copper chelation with 
 75
either D-penicillamine or Zinc or both sequentially. All except 3 had improvement 
in clinical and laboratory parameters. Drinking water that was collected from the 
patients’ residences right from the birth for copper content showed normal water 
copper levels (2.32 µg/L, 0.32-8.9) (median, range ). The action level for water 
copper level is 1300ug/L. The drinking water copper levels collected from the 
patients’ residences were well below the action level stating that copper 
accumulation in the liver is not due to increased exogenous intake. 
 
Further more, though phenotype was no different from WD, the laboratory 
parameters were not correlating with WD. ATP 7B mutations screening using 
Conformation sensitive gel electrophoresis in 6 patients tested were shown 
negative . 
The histological features that can distinguish ACLD from WD and ICC are 
depicted in table 8 
 Fatty change Peri cellular 
fibrosis 
Mallory hyaline 
ACLD no fatty change mild abundant 
           WD glycogenated cells nil present 
            ICC no fatty change creeping fibrosis abundant 
 
Table 9 Differentiation  of ACLD  from WD and ICC 
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The hepatic copper accumulation in Wilson’s disease is now thought to be due to 
defective functioning of ATP 7B protein (the product of the Wilson’s disease gene 
or ATP 7B gene). ATP 7B protein is postulated to facilitate copper excretion 
across the canalicular membrane into the biliary canaliculus. In Indian Childhood 
Cirrhosis, contaminaiton of milk was thought to be the cause of increased copper 
content in the liver. The hepatic copper deposition in ACLD may probably due to a 
defect in the copper metabolism other than WD. It may be a genetic disorder as 
was seen occurring in siblings in two families or it may be expressing in 
conjunction with an unknown environmental toxin. 
 
Earlier studies by Muller et al 81 provided strong evidence that Idiopathic copper 
toxicosis or endemic infantile Tyrolean cirrhosis is an ecogenetic disorder affecting 
a genetically predisposed fraction of the population, and requiring both 
homozygosity for a defective gene and high levels of exogenous copper for disease 
manifestation. The likelihood that the abnormal gene persists in healthy 
heterozygous siblings should enable its identification, thereby proving that we are 
dealing with a genetic disorder of copper metabolism. 
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ACLD has to be kept as a differential diagnosis while one is dealing with any of 
the copper related liver diseases. The diagnosis was established largely by liver 
biopsy in the above patients underscores the importance of liver biopsy in 
investigating cryptogenic liver disease. The diagnosis would have been missed in 
all these patients if liver biopsy would not have been performed and hence copper 
chelation. 
 
In this study there was no exogenous copper intake that was demonstrated. With 
regard to the genetic aspects of the disease ATP 7B gene mutations was not found 
indicating that there may be unknown defects in other part of the genome that is 
responsible for the expression of the disease. 
 
Further studies that look into the copper kinetics, characterization of ATP 7 B 
protein, other copper transporting molecules and any other defect in the copper 
metabolism needs to be performed 
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Conclusion  
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 The conclusions drawn from this study are 
 
 
1. The 11 patients have features of hepatic copper overload not fitting into 
either WD or ICC 
2. This condition is different from WD by not showing neurological 
involvement  and  coombs negative heamolytic aneamia with normal 
ceruloplasmin, and negative for Kayser Fleisher rings and ATP 7 B 
mutations. 
3. This condition is different from ICC by the occurrence of disease after 5 
years with no dietary history of copper intake and histology different from 
ICC. 
4. The treatment outcome of  ACLD patients with either Penicillamine or Zinc 
or both sequentially is good. 
5. There was no evidence for increased copper intake in drinking water in 
ACLD patients studied. 
6. Further studies into causation of ACLD are needed .  
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APPENDIX  I - PROFORMA 
 
 
Case Number  
Name 
Age 
Sex  
Hospital number 
Address  
Date of illness 
Date of CMC Consultation 
Date of diagnosis 
Final diagnosis and basis of diagnosis 
Date of starting of treatment 
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Clinical details 
Jaundice:  
Cholestatic or non cholestatic 
Duration  
Prodrome 
Associated with hepatic decompensation 
Abdominal distension : 
Uniform 
Painless or painful 
Intermittent or progressive 
Pedal oedema 
Altered sensorium  
Other complications 
Oliguria 
Fever  
Weight loss and loss of apetite 
 95
Drug intake  
Dietary history 
Family history  
Personal history 
Social history 
Treatment history 
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Physical examination  
 
Height :                    weight :                    BMI : 
Pallor  
Icterus 
Clubbing 
Cyanosis 
Pedal oedema 
Lymphadenopathy 
 
 
 
 
Systemic examination  
 
Abdominal : 
 
Respiratory : 
 
Cardiovascular : 
 
Others: 
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Investigations 
 
1.  Complete blood profile 
     Liver function tests 
     Prothrombin time, Activated partial thromboplastin time 
     Serum creatinine and electrolytes 
 
2.  Radiological and endoscopy  tests 
     Chest x ray PA view 
     USG abdomen 
     Oesophagogastroduodenoscopy  
 
3.  Etiological work up for liver disease 
     Blood borne virus infection  
     Antinuclear antibody  
     Serum immunoglobulins 
     Total core antibody 
 
4.  Wilsons’ Disease work up 
     Serum ceruloplasmin 
     24 hr urinary copper 
     Hepatic copper estimation  
     KF ring 
     ATP 7B mutation analysis 
 
5.  liver biopsy ( percutaneous / transjugular) 
 
6. Drinking water copper level 
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APPENDIX – II MASTER SHEET 
 
 
 
 
 
 
S No Patient name 
Hospital 
no. Age Sex 
Date of 
illness 
Date of 
CMC 
Initiation 
of 
treatment KF ring 
        
present-
2 
absent-
0 
1 Vinoth kumar 848905c 22 M Sep-06 Sep-06 Sep-06  Neg 
2 Prem kumar  110163d 9 M Sep-07 Oct-07 Oct-07  neg 
3 Krystal 000929d 18 F Jun-05 Apr-07 Apr-07  Neg 
4 Mubthi 080334d 15 M Aug-07 Sep-07 Oct-07  Neg 
5 Krishna raj 993332c 9 M Mar-06 Mar-07 Mar-07  neg 
6 siva kumar 778355b 15 M Oct-99 Oct-99 Dec-99  neg 
7 monica 795562b 14 F  Oct-99 Dec-99  neg 
8 purushothaman 792595b 13 M  Oct-99 Dec-99  Neg 
9 smitha rajan 061183d 24 F Jun-03 Jun-07 Jul-07 positive  
10 chenna kesava 172104d 23 M Jan-05 Jan-08 Mar-08  Neg 
11 sobika 278652c 9 F Aug-04 Sep-04 Sep-04  Neg 
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neurological symptoms 
Coomb's negative 
heamolytic aneamia ceruloplasmin 
severe-2 mild-1 absent-0 present-1 absent-0 normal-0 half-1 less-2 
  abs  abs 175   
  abs  abs 129   
  abs  abs  50  
  abs  abs 81   
  abs  abs  59  
  abs  abs 92   
  abs  abs 78   
  abs  abs 176   
  abs  abs 104   
  abs  abs 379 new   
  abs  abs 62   
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urine copper liver copper rhodanine stain 
normal-
0 
1-2x 
ULN 
>2x 
ULN 
>5ULN,post 
pencillamine 
<50ug - 
-1 
50-250 - 
1 >250 - 2 
absent 
- 0 
present 
- 1 
 145     813ug /g  present 
   1272     present 
78        present 
111   809   596 ug/g absent  
21        present 
94        present 
87        present 
68        present 
 189     449ug/g  present 
95      390ug/g  present 
 122       present 
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mutation analysis water copper level 
2 muta - 4 1 muta - 2 no muta- 0   
  neg 2.86  
   2.36  
  neg 4.04  
   1.08  
   0.32  
  neg 0.7  
  neg 0.7  
  neg 0.7  
  neg 1.2  
   2.68  
   8.9  
     
   2.32  
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Leipzig 
score                                                  MELD 
 base line 6 months 1 year  1.5years 2years 2.5years 3years 
4 10 13 14 13 11   
3 18 11 10     
2 16 18 21 26    
4 13 15 11     
2 15 8 7 7    
2 18 16 17 13 16 14 8 
1 6 6 6 6    
1 12 7 6 6    
4 13 10 9 8    
3 17 15      
2 7 13 12 9 8   
        
Median 13 13 10.5 8.5    
Mean 13.18 12 11.3 11    
 
Albumin 
base line 6 months 1 year  1.5years 2years 2.5years 3years 
3.7 3.4 2.3 2.2 1   
2.3 2.9 3.4     
2.4 2.5 1.9 2.6    
2.1 3.2 3.9     
1.6 3.1 2.9 2.4    
2.6 2.9 3.9 2.3 2.9 2.8 3 
3.7 4.1 4.2 4.4    
2.9 3.9 4.4 4.4    
2 2.4 2.6 2.6    
2.3 2.8      
5 3.6 3.3 3.6 4.7   
       
2.4 3.1 3.35 2.6    
2.78 3.16 3.28 3.06    
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CTP Score 
base line 6 months 1 year  1.5years 2years 2.5years 3years 
6 7 10 10 11   
11 8 6     
10 11 12 13    
10 9 6     
10 7 7 7    
11 10 9 9 9 9 7 
5 5 5 5 5   
9 5 5 5    
10 8 8 8    
12 9      
5 7 8 6 5   
       
10 8 7.5 7.5    
9 7.8 7.6 7.8    
      
 
bilirubin mg/dl 
base line 6 months 1 year  1.5years 2years 2.5years 3years 
1.9 3.3 3.8 3.2 2.4   
4.1 1.7 1.4     
3 3.7 9.4 42.1    
1.5 1.9 0.9     
3 0.6 0.6 1    
5.3 4 5.3 2.5 3 2.6 1.7 
0.3 0.6 0.7 0.5    
2.7 0.9 0.9 0.9    
3.2 1.5 1.5 1.3    
2.7 2.5      
0.8 2.3 1.6 1 0.6   
       
2.7 1.8 1.4 1    
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24hr urine copper ug/24 hr 
base line 6 months 1 year  1.5years 2years 2.5years 3years 
145       
1272 368      
78       
809  73     
21 81      
150 672      
87 490 154 48    
48 705 104 38    
189 72      
95       
256 663 411 64 77   
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                        Legends 
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Table1:Amplimers and Annealing Temp. for CSGE analysis and sequencing 
Table 2 : Patient characteristics 
Table 3 : Clinical presentation of patients 
Table 4 shows the investigative profile of the patients. 
Table 5 Leipzig scoring 
Table 6:  Leipzig scoring system for ACLD patients 
Table 7 : Liver biopsy findings in all patients 
Table 8:  Drinking water copper levels 
Table 9 Differentiation  of ACLD  from WD and ICC 
 
 
 
 
Fig 1 , CSGE results of exon 11 in three patients 
Fig 2 , CSGE results of exon 19 in three patients 
Fig 3.  Distribution of patients by state of origin 
Fig 4 Orcein stain shows fine  granules of copper associated protein in 
periportal hepatocytes (Orcein X 400) in patient 6 
Fig 5 Rhodanine stain shows  granular deposits of copper in periportal 
hepatocytes (Rhodamine X 400) in patient 6 
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Graph 1 showing Mean MELD score on followup of ACLD patients 
Graph 2 showing Mean Albumin levels on followup 
Graph 3 showing Mean CTP score on followup 
Graph 4 showing Mean Bilirubin on followup 
Graph 5 showing Mean 24 hr urine copper levels on followup 
Graph 6 showing duration of treatment with copper chelation 
 
